Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 4100 participants.
Also called NCT05881382
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,100 participants
- Sponsor
- Recardio, Inc.
- Registry
-
NCT05881382
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05881382. Randomized; quadruple masking; primary purpose treatment. Start 2023-09 (anticipated); primary completion 2025-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
- Acronym
- HEAL-MI
- Condition
- ST Elevation Myocardial Infarction
- Intervention (Drug)
- Dutogliptin + Filgrastim
- Intervention (Drug)
- Placebo
- Lead sponsor
- Recardio, Inc.
Record details
- Record id
cardio:ct-nct05881382- Content hash
d523572d151d34bea4b58e9657ac2cc42749e20d74560663f3559084c9211f0b